Improved quality of life in immunocompromised patients opens travel opportunities, but administering the yellow fever (YF) vaccine is often contraindicated. We advocate re-evaluating this position for immunocompromised patients who travel frequently or who are migrating to regions in which YF is endemic.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735878PMC
http://dx.doi.org/10.1093/jtm/taz015DOI Listing

Publication Analysis

Top Keywords

yellow fever
8
immunocompromised patients
8
fever vaccination
4
vaccination immunocompromised
4
immunocompromised travellers
4
travellers unjustified
4
unjustified vaccination
4
vaccination hesitancy?
4
hesitancy? improved
4
improved quality
4

Similar Publications

Background: Traveller's health is one of the factors determining the success of his or her visit to the destination. The health aspects before, during and after travel are often neglected which may lead to untoward incidences during or after travel. Also, with the increase in national and international travel many emerging and re-emerging diseases are on the rise.

View Article and Find Full Text PDF

Rapid urbanization and migration in Latin America have intensified exposure to insect-borne diseases. Malaria, Chagas disease, yellow fever, and leishmaniasis have historically afflicted the region, while dengue, chikungunya, and Zika have been described and expanded more recently. The increased presence of synanthropic vector species and spread into previously unaffected areas due to urbanization and climate warming have intensified pathogen transmission risks.

View Article and Find Full Text PDF

With their diverse species, mosquitoes are known to transmit the causal agents of diseases such as malaria, dengue, and yellow fever. Their high adaptability, attraction to humans, and variable adult behaviors make them a significant health concern. The focus on Aedes aegypti is significant for reducing vector-human contacts, monitoring insecticide resistance, and developing innovative vector management strategies.

View Article and Find Full Text PDF

: Yellow fever (YF) outbreaks continue to affect populations that are not reached by routine immunization services, such as workers at a high risk of occupational exposure to YF. In the Central African Republic (CAR), YF cases were detected in districts characterized by the presence of workers in forest areas. We developed an innovative approach based on a local partnership with private companies of the extractive industry to administer YF vaccine to workers in remote areas during the response to an outbreak.

View Article and Find Full Text PDF

: Yellow fever virus (YFV) (, ) is the etiologic agent of yellow fever (YF), a vector-borne disease with significant morbidity and mortality across the tropics and neotropics, despite having a highly efficacious and safe vaccine (17D). Vaccination provides lifelong protection from YF disease mediated by humoral immunity. There are several versions of the original 17D vaccine: 17D-204 (marketed in the USA as YF-VAX, in France as Stamaril, and in China as Tiantan-V), 17D-213 (Russian Federation), and 17DD (by FIOCRUZ in Brazil).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!